The drug manufacturer Aurobindo Pharma Ltd., situated in Hyderabad, told the exchanges on Friday that the United States Food and Drug Administration (USFDA) had sent a warning notice to its Unit-III, a formulations manufacturing facility of Eugia Pharma Specialties Ltd.
Eugia Pharma is a completely owned subsidiary of Aurobindo Pharma.
Following the USFDA observation, the Pashamylaram-based unit was granted Official Action Indicated (OAI) status in May of this year.
The USFDA issues warning letters to companies to inform them of concerns about their actions. Warning letters can be sent for several reasons, such as poor manufacturing practices, issues with product claims, or improper usage instructions.
According to Aurobindo Pharma’s exchange report, the current supply to the US markets is unaffected.
As of 10:55 am, Aurobindo Pharma shares were trading 2.93% lower at Rs 1,475.20 on the NSE.
Disclaimer: The information provided in this article is for informational purposes only and should not be considered as financial advice. The data and figures presented are based on publicly available information and may be subject to change. Before making any investment decisions, it is recommended to conduct thorough research, consult with financial advisors, and consider your individual investment goals and risk tolerance. The author and publisher of this article do not assume any responsibility for any investment decisions made based on the information provided.